Aardvark Therapeutics, Inc. (AARD)
Health Care · Rare disease therapeutics / orphan drugs · Nasdaq
Clinical-stage biopharmaceutical company developing ARD-101 and other therapeutic candidates focused on rare genetic disorders including Prader-Willi Syndrome.
What Aardvark Therapeutics, Inc. does
Aardvark Therapeutics is a clinical-stage biopharmaceutical company with a limited operating history and no approved products. The company is developing product candidates targeting rare genetic disorders, with ARD-101 as its lead program. The company relies on third-party manufacturers for clinical supplies and conducts its preclinical studies and clinical trials through third-party relationships.
Themes: ["Rare / orphan diseases","Prader-Willi Syndrome (PWS)","Clinical-stage development","Biopharmaceutical"]
Fundamentals
- Price$7.60 as of 2026-07-10 close
- Market cap$166M as of 2026-07-13
- 1-year return-39.7% as of 2026-07-10 close
- ROE-61.7% as of 2026-07-13
- Debt / equity0.00 as of 2026-07-13
- Beta3.65 as of 2026-07-13
Key risks (from latest filing)
["Clinical-stage company with no approved products and uncertain ability to obtain regulatory approval; ARD-101 and other candidates face lengthy, unpredictable FDA approval processes with no guarantee of success.","Substantial additional capital required; failure to secure financing on acceptable terms could force delays or termination of development programs.","Heavy dependence on third-party manufacturers and clinical trial contractors; manufacturing delays, quality issues, regulatory non-compliance, or contract termination could halt or delay commercialization."]
Fundamentals: Finnhub, as of 2026-07-13. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-10.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.